Progressing existing snake venom toxin-specific antibodies into humanised, thermostable monoclonal therapies for preclinical manufacture and clinical trials in Africa and India
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.